Literature DB >> 34505979

Neighborhood Socioeconomic Disadvantage and Mortality Among Medicare Beneficiaries Hospitalized for Acute Myocardial Infarction, Heart Failure, and Pneumonia.

Zachary Hermes1,2, Karen E Joynt Maddox3, Robert W Yeh1, Yuansong Zhao1, Changyu Shen1, Rishi K Wadhera4.   

Abstract

BACKGROUND: The Centers for Medicare and Medicaid Services' Hospital Value-Based Purchasing program uses 30-day mortality rates for acute myocardial infarction, heart failure, and pneumonia to evaluate US hospitals, but does not account for neighborhood socioeconomic disadvantage when comparing their performance.
OBJECTIVE: To determine if neighborhood socioeconomic disadvantage is associated with worse 30-day mortality rates after a hospitalization for acute myocardial infarction (AMI), heart failure (HF), or pneumonia in the USA, as well as within the subset of counties with a high proportion of Black individuals. DESIGN AND PARTICIPANTS: This retrospective, population-based study included all Medicare fee-for-service beneficiaries aged 65 years or older hospitalized for acute myocardial infarction, heart failure, or pneumonia between 2012 and 2015. EXPOSURE: Residence in most socioeconomically disadvantaged vs. less socioeconomically disadvantaged neighborhoods as measured by the area deprivation index (ADI). MAIN MEASURE(S): All-cause mortality within 30 days of admission. KEY
RESULTS: The study included 3,471,592 Medicare patients. Of these patients, 333,472 resided in most disadvantaged neighborhoods and 3,138,120 in less disadvantaged neighborhoods. Patients living in the most disadvantaged neighborhoods were younger (78.4 vs. 80.0 years) and more likely to be Black adults (24.6% vs. 7.5%) and dually enrolled in Medicaid (39.4% vs. 21.8%). After adjustment for demographics (age, sex, race/ethnicity), poverty, and clinical comorbidities, 30-day mortality was higher among beneficiaries residing in most disadvantaged neighborhoods for AMI (adjusted odds ratio 1.08, 95% CI 1.06-1.11) and pneumonia (aOR 1.05, 1.03-1.07), but not for HF (aOR 1.02, 1.00-1.04). These patterns were similar within the subset of US counties with a high proportion of Black adults (AMI, aOR 1.07, 1.03-1.11; HF 1.02, 0.99-1.05; pneumonia 1.03, 1.00-1.07).
CONCLUSIONS: Neighborhood socioeconomic disadvantage is associated with higher 30-day mortality for some conditions targeted by value-based programs, even after accounting for individual-level demographics, clinical comorbidities, and poverty. These findings may have implications as policymakers weigh strategies to advance health equity under value-based programs.
© 2021. Society of General Internal Medicine.

Entities:  

Mesh:

Year:  2021        PMID: 34505979      PMCID: PMC9198133          DOI: 10.1007/s11606-021-07090-z

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  38 in total

1.  The Sociology of Discrimination: Racial Discrimination in Employment, Housing, Credit, and Consumer Markets.

Authors:  Devah Pager; Hana Shepherd
Journal:  Annu Rev Sociol       Date:  2008-01-01

2.  Disparities in Cardiovascular Mortality Related to Heart Failure in the United States.

Authors:  Peter Glynn; Donald M Lloyd-Jones; Matthew J Feinstein; Mercedes Carnethon; Sadiya S Khan
Journal:  J Am Coll Cardiol       Date:  2019-05-14       Impact factor: 24.094

3.  For blacks in America, the gap in neighborhood poverty has declined faster than segregation.

Authors:  Glenn Firebaugh; Francesco Acciai
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

Review 4.  Structural racism and health inequities in the USA: evidence and interventions.

Authors:  Zinzi D Bailey; Nancy Krieger; Madina Agénor; Jasmine Graves; Natalia Linos; Mary T Bassett
Journal:  Lancet       Date:  2017-04-08       Impact factor: 79.321

5.  Life Course Approaches to the Causes of Health Disparities.

Authors:  Nancy L Jones; Stephen E Gilman; Tina L Cheng; Stacy S Drury; Carl V Hill; Arline T Geronimus
Journal:  Am J Public Health       Date:  2019-01       Impact factor: 9.308

6.  Characteristics of hospitals receiving penalties under the Hospital Readmissions Reduction Program.

Authors:  Karen E Joynt; Ashish K Jha
Journal:  JAMA       Date:  2013-01-23       Impact factor: 56.272

7.  Financial Incentives and Vulnerable Populations - Will Alternative Payment Models Help or Hurt?

Authors:  Karen E Joynt Maddox
Journal:  N Engl J Med       Date:  2018-03-15       Impact factor: 91.245

8.  Neighborhood of residence and incidence of coronary heart disease.

Authors:  A V Diez Roux; S S Merkin; D Arnett; L Chambless; M Massing; F J Nieto; P Sorlie; M Szklo; H A Tyroler; R L Watson
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

9.  Accounting For Patients' Socioeconomic Status Does Not Change Hospital Readmission Rates.

Authors:  Susannah M Bernheim; Craig S Parzynski; Leora Horwitz; Zhenqiu Lin; Michael J Araas; Joseph S Ross; Elizabeth E Drye; Lisa G Suter; Sharon-Lise T Normand; Harlan M Krumholz
Journal:  Health Aff (Millwood)       Date:  2016-08-01       Impact factor: 6.301

10.  Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry.

Authors:  Adam N Berman; David W Biery; Curtis Ginder; Avinainder Singh; Jonggyu Baek; Rishi K Wadhera; Wanda Y Wu; Sanjay Divakaran; Ersilia M DeFilippis; Jon Hainer; Christopher P Cannon; Jorge Plutzky; Donna M Polk; Khurram Nasir; Marcelo F Di Carli; Arlene S Ash; Deepak L Bhatt; Ron Blankstein
Journal:  JAMA Cardiol       Date:  2021-08-01       Impact factor: 14.676

View more
  1 in total

Review 1.  Society of General Internal Medicine Position Statement on Social Risk and Equity in Medicare's Mandatory Value-Based Payment Programs.

Authors:  Anders Chen; Arnab Ghosh; Kendrick B Gwynn; Celeste Newby; Tracey L Henry; Jackson Pearce; Marshall Fleurant; Stacie Schmidt; Jennifer Bracey; Elizabeth A Jacobs
Journal:  J Gen Intern Med       Date:  2022-06-29       Impact factor: 6.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.